Skip to main content

Table 4 Data collection elements

From: Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol

Category Specific items
Study characteristics Study title, author, date of publication, journal published, sponsorship, country of publication
Study population (animal model) Animal type, age, gender, strain, and weight, presence of co-morbid illnesses
Type of acute lung injury model Direct infection, indirect infection, ventilator-induced injury, chemical-induced injury, trauma, shock, pancreatitis, ischemia-reperfusion
Severity of experimentally induced acute lung injury According to the lung injury score [16]
Intervention and comparison Time and route given, description of preparation and suspension of MSCs and controls
Co-interventions Resuscitation fluids, antibiotics, and mechanical ventilation
Preclinical endpoints Death, features and measures of acute lung injury (Table 3) that include: histological evidence of pulmonary injury;alteration in alveolar capillary barrier;pulmonary and systemic inflammatory response; measurements of physiological dysfunction; and pathogen clearance (measured using the number of bacterial colony forming units in lung, liver, spleen, and blood), and adverse events
Risk of bias assessments In accordance with the Cochrane risk of bias tool, allocation concealment, randomization, blinding (personnel, endpoint measurements), and endpoint measures (completeness of follow-up)
Quality of reporting of individual preclinical studies In accordance with elements of the ARRIVE guidelines [42]
Other Industry sponsorship, single centre versus multi-centre, and presence of a priori sample size calculation.
  1. ARRIVE, Animal Research: Reporting of In Vivo Experiments; MSC, mesenchymal stromal cell.